размер рынка лечения сду/тэн, доля и мировые тенденции к 2030 году

Global Sjs Ten Treatment Market

Размер рынка в млрд долларов США

CAGR : 7.60 %

Прогнозируемый период	2023 –2030
Размер рынка (базовый год)	USD 7,100.00 Million
Размер рынка (прогнозируемый год)	USD 12,586.71 Million
CAGR	7.60 %
Основные игроки рынка	3M Cardinal Health BD Smith + Nephew Novartis AG

>Глобальный рынок лечения синдрома Стивенса-Джонсона/теннисного нефрита, по лечению (лекарства, поддерживающая терапия, госпитализация, изоляция, мази и другие), диагнозу (физический осмотр, биопсия кожи , история болезни, анализ крови, посевы и другие), причине (специфическое лечение, инфекция и другие), способу введения (перорально, парентерально, местно и другие), типу препарата (фирменный и дженерик), области терапии (комбинированная терапия и монотерапия), типу пациента (гериатрический, взрослый и детский), конечному пользователю (больницы, специализированные клиники, амбулаторные хирургические центры, учреждения по уходу на дому и другие), каналу сбыта (розничные аптеки, прямые торги и другие) — тенденции отрасли и прогноз до 2030 года.

Анализ рынка лечения SJS/TEN и его понимание

Рынок лечения синдрома Стивенса-Джонсона (ССД) и токсического эпидермального некролиза (ТЭН) относительно невелик из-за редкости этих заболеваний.

На мировом рынке лечения SJS/TEN доминируют лекарственные препараты, поскольку они являются основной формой лечения этих состояний. Кортикостероиды, внутривенный иммуноглобулин (IVIG) и антибиотики являются наиболее часто используемыми препаратами при лечении SJS/TEN.

Ожидается, что мировой рынок лечения синдрома Стивенса-Джонсона/теннисного некроза будет расти в прогнозируемый период с 2023 по 2030 год. По данным Data Bridge Market Research, среднегодовой темп роста рынка составит 7,6% в прогнозируемый период с 2023 по 2030 год, и ожидается, что к 2030 году объем рынка достигнет 12 586,71 млн долларов США по сравнению с 7 100,00 млн долларов США в 2022 году.

Отчет о мировом рынке лечения SJS/TEN содержит подробную информацию о доле рынка, новых разработках и анализе линейки продуктов, влиянии внутренних и локальных игроков рынка, анализирует возможности с точки зрения новых источников дохода, изменений в рыночных правилах, одобрений продуктов, стратегических решений, запусков продуктов, географических расширений и технологических инноваций на рынке. Чтобы понять анализ и рыночный сценарий, свяжитесь с нами для получения аналитического резюме. Наша команда поможет вам создать решение по влиянию на доход для достижения желаемой цели. Масштабируемость и расширение бизнеса розничных подразделений в развивающихся странах различных регионов и партнерство с поставщиками для безопасного распространения машин и лекарственных препаратов являются основными факторами, которые стимулировали спрос на рынке в прогнозируемый период.

Отчет Метрика	Подробности
Прогнозируемый период	2023-2030
Базовый год	2022
Исторические годы	2021 (Можно настроить на 2015 - 2020)
Количественные единицы	Доход в млн. долл. США
Охваченные сегменты	Лечение (лекарства, поддерживающая терапия, госпитализация, изоляция, мази и др.), Диагностика (физический осмотр, биопсия кожи, история болезни, анализ крови, посевы и др.), Причина (специфическое лечение, инфекция и др.), Способ применения (пероральный, парентеральный, местный и др.), Тип препарата (фирменный и дженерик), Терапевтическая область (комбинированная терапия и монотерапия), Тип пациента (гериатрический, взрослый и детский), Конечный пользователь (больницы, специализированные клиники, амбулаторный хирургический центр, учреждения по уходу на дому и др.), Канал сбыта (розничные аптеки, прямой тендер и др.)
Страны, охваченные	США, Канада, Мексика, Германия, Великобритания, Франция, Италия, Россия, Испания, Нидерланды, Дания, Швейцария, Швеция, Польша, Норвегия, Финляндия, Бельгия, Турция, Остальная Европа, Китай, Япония, Индия, Новая Зеландия, Австралия, Южная Корея, Индонезия, Филиппины, Таиланд, Малайзия, Сингапур, Вьетнам, Тайвань, Остальная часть Азиатско-Тихоокеанского региона, Саудовская Аравия, Южная Африка, Бахрейн, Кувейт, Оман, Катар, ОАЭ, Египет, Израиль и Остальная часть Ближнего Востока и Африки, Бразилия, Аргентина, Остальная часть Южной Америки
Охваченные участники рынка	3M (США), Cardinal Health (США), BD (США), Smith + Nephew (Великобритания), Novartis AG (Швейцария), Amneal Pharmaceuticals LLC. (США), Amgen Inc. (США), Pfizer Inc. (США), Colgate-Palmolive Company (США), Merck & Co., Inc. (США), Mölnlycke Health Care AB. (Швеция), Xttrium Laboratories (США), Schülke & Mayr GmbH (Германия), ICPA Health Products Ltd (Индия), Purdue Pharma LP (США), eugia (дочерняя компания Aurobindo Pharma) и AdvaCare Pharma (США) и другие

Определение рынка

Синдром Стивенса-Джонсона (SJS) и токсический эпидермальный некролиз (TEN) — редкие, но опасные для жизни заболевания кожи, которые обычно возникают в результате тяжелых лекарственных реакций. Эти состояния приводят к отделению верхнего слоя кожи от нижних слоев, что приводит к появлению болезненных волдырей и язв, которые могут покрывать большую часть тела. SJS поражает меньшую часть кожи, тогда как TEN поражает большую часть кожи.

Определение лечения SJS/TEN относится к продуктам и услугам, разработанным для управления и лечения этих состояний. На рынке есть лекарства, терапии и другие методы лечения, которые могут помочь облегчить симптомы SJS/TEN и улучшить качество жизни пациентов. Рынок лекарств для лечения SJS/TEN включает ряд препаратов, которые используются для облегчения симптомов и лечения основной причины.

Динамика мирового рынка лечения SJS/TEN

В этом разделе рассматривается понимание движущих сил рынка, преимуществ, ограничений и проблем. Все это подробно обсуждается ниже:

Драйверы

Рост распространенности и заболеваемости синдромом Стивенса-Джонсона/тен-энцефалитом

Синдром Стивенса-Джонсона (SJS) и токсический эпидермальный некролиз (TEN) являются серьезными и потенциально опасными для жизни состояниями, затрагивающими кожу и слизистые оболочки. SJS и TEN считаются двумя концами спектра заболеваний, причем SJS является более легкой формой, а TEN — более тяжелой. Характерной чертой этих состояний является отделение эпидермиса (внешнего слоя кожи) от дермы (слоя под кожей) из-за сильной иммунной реакции.

Синдром Стивенса-Джонсона (SJS) и токсический эпидермальный некролиз (TEN) — редкие, но серьезные заболевания кожи, характеризующиеся отделением эпидермиса от дермы. Сообщается, что заболеваемость SJS/TEN составляет около 1 на миллион человек в год. Однако в последние годы возросла обеспокоенность по поводу заболеваемости и распространенности SJS/TEN.

Достижения в разработке лекарственных препаратов для лечения SJS/TEN

Синдром Стивенса-Джонсона (SJS) и токсический эпидермальный некролиз (TEN) являются серьезными и потенциально опасными для жизни состояниями, требующими немедленного и агрессивного лечения. Хотя в настоящее время нет специального лекарства или лечения, которые могут вылечить SJS/TEN, достижения в разработке лекарств привели к улучшению стратегий лечения и результатов лечения для затронутых пациентов. Но проводятся различные клинические испытания по разработке лекарств для лечения SJS/TEN.

Сдержанность

Высокая стоимость лечения синдрома Стивенса-Джонсона/тен-энцефалита

Одной из главных причин, по которой лечение SJS/TEN является дорогостоящим, является необходимость интенсивного и длительного лечения. Пациентам с SJS/TEN часто требуется госпитализация в специализированные ожоговые отделения, где они получают круглосуточную помощь от команды медицинских работников, включая дерматологов, офтальмологов и специалистов по интенсивной терапии. Госпитализация может длиться несколько недель, а в тяжелых случаях даже месяцев. Это может привести к высоким больничным счетам и другим сопутствующим расходам, таким как транспорт, проживание и питание.

Возможность

Разработка эффективного и безопасного лечения синдрома Стивенса-Джонсона/тен-энцефалического синдрома

Трансплантация стволовых клеток — это новый подход, направленный на замену поврежденной кожи и слизистых оболочек здоровой тканью. Аутологичная трансплантация стволовых клеток, при которой стволовые клетки берутся из кожи пациента и выращиваются в культуре перед пересадкой обратно в поврежденную область, показала многообещающие результаты в небольших исследованиях.

Испытание

Строгие правительственные правила утверждения лечения синдрома Стивенса-Джонсона/тенденциозного энцефалита

Строгие государственные правила одобрения методов лечения синдрома Стивенса-Джонсона/тенефрита связаны со сложным и строгим процессом, который должны пройти фармацевтические компании и их препараты, чтобы получить одобрение на лечение синдрома Стивенса-Джонсона/тенефрита от регулирующих органов, таких как Управление по контролю за продуктами и лекарствами США (FDA) или Европейское агентство по лекарственным средствам (EMA).

Процесс одобрения нового препарата обычно включает несколько этапов клинических испытаний на людях для оценки безопасности и эффективности препарата.

Последние события

В июне 2020 года BD, ведущая мировая компания в области медицинских технологий, объявила о завершении приобретения частной компании Straub Medical AG. Благодаря этому приобретению компания приобрела ценные знания и опыт Straub Medical AG и расширила свой продуктовый портфель. Это поможет компании расширяться и расти на рынке.
В январе 2019 года Mölnlycke Health Care AB. приобретает MandJ Airlaid Products A/S для дальнейшего укрепления своих возможностей по уходу за ранами. В связи с приобретением MandJ и его сотрудники станут неотъемлемой частью Mölnlycke. Приобретение улучшит безопасность поставок Mölnlycke материала Airlaid, необходимого для производства современных раневых повязок, и поможет развитию бизнеса по уходу за ранами за счет ускорения инноваций и разработки продукции в существующих и будущих продуктах. Это поможет компании расширяться и расти на рынке.

Масштаб мирового рынка лечения SJS/TEN

Глобальный рынок лечения SJS/TEN подразделяется на девять примечательных сегментов на основе лечения, диагностики, причины, пути введения, типа препарата, типа терапии, типа пациента, конечного пользователя и канала распространения. Рост среди сегментов помогает вам анализировать нишевые карманы роста и стратегии для выхода на рынок и определять ваши основные области применения и разницу в ваших целевых рынках.

Глобальный рынок лечения синдрома Стивенса-Джонсона/тенденциозного некроза делится на девять основных сегментов в зависимости от лечения, диагностики, причины, пути введения, типа препарата, типа терапии, типа пациента, конечного пользователя и канала сбыта.

Уход

Лекарства
Поддержка Уход
Мази
Госпитализация
Изоляция
Другие

По принципу лечения глобальный рынок лечения синдрома Стивенса-Джонсона/тенденциозного эпилептического синдрома (ТЭН) сегментируется на лекарственные препараты, поддерживающую терапию, госпитализацию, изоляцию, мази и другие.

Диагноз

Физический осмотр
История болезни
Биопсия кожи
Анализ крови
Культуры
Другие

На основе диагностики глобальный рынок лечения ССД/ТЭН сегментируется на физикальный осмотр, биопсию кожи, историю болезни, анализ крови, посевы и другие.

Причина

Специфическое лечение
Инфекция
Другие

В зависимости от причины мировой рынок лечения ССД/ТЭН сегментируется на специфическое лечение, инфекционное лечение и другие.

Путь введения

Оральный
Парентеральный
Актуальный
Другие

В зависимости от способа введения мировой рынок средств для лечения синдрома Стивенса-Джонсона/теннисного некроза делится на пероральные, парентеральные, местные и другие.

Тип препарата

Фирменный
Общий

По типу препарата мировой рынок средств для лечения синдрома Стивенса-Джонсона/теннисного некроза делится на брендовые и дженерики.

Тип терапии

Монотерапия
Комбинированная терапия

По типу терапии мировой рынок лечения ССД/ТЭН сегментируется на комбинированную терапию и монотерапию.

Тип пациента

Педиатрический
Взрослый
гериатрический

В зависимости от типа пациента мировой рынок лечения синдрома Стивенса-Джонсона/ТЭН подразделяется на гериатрический, взрослый и детский.

Конечный пользователь

Больницы
Специализированные клиники
Амбулаторный хирургический центр
Уход на дому
Другие

В зависимости от конечного пользователя глобальный рынок лечения синдрома Стивенса-Джонсона/тенденциозного эпилептического синдрома сегментирован на больницы, специализированные клиники, амбулаторные хирургические центры, учреждения по уходу на дому и другие.

Канал распространения

Прямые тендеры
Розничные аптеки
Другие

По каналам сбыта мировой рынок лечения синдрома Стивенса-Джонсона/теннисного некроза делится на розничные аптеки, прямые тендеры и другие.

Региональный анализ/информация о мировом рынке лечения SJS/TEN

Страны, охваченные данным отчетом о рынке: США, Канада, Мексика, Германия, Великобритания, Франция, Италия, Россия, Испания, Нидерланды, Дания, Швейцария, Швеция, Польша, Норвегия, Финляндия, Бельгия, Турция, остальные страны Европы, Китай, Япония, Индия, Новая Зеландия, Австралия, Южная Корея, Индонезия, Филиппины, Таиланд, Малайзия, Сингапур, Вьетнам, Тайвань, остальные страны Азиатско-Тихоокеанского региона, Саудовская Аравия, Южная Африка, Бахрейн, Кувейт, Оман, Катар, ОАЭ, Египет, Израиль, остальные страны Ближнего Востока и Африки, Бразилия, Аргентина, остальные страны Южной Америки.

Ожидается, что Азиатско-Тихоокеанский регион будет доминировать на мировом рынке лечения SJS/TEN. Китай доминирует в Азиатско-Тихоокеанском регионе из-за присутствия ключевых игроков на крупнейшем потребительском рынке с высоким ВВП.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, заменяющие продажи, демографические данные страны, нормативные акты и импортно-экспортные тарифы, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по стране учитываются наличие и доступность глобальных брендов и их проблемы из-за большой или малой конкуренции со стороны местных и внутренних брендов, а также влияние каналов продаж.

Конкурентная среда и глобальный анализ доли рынка лечения SJS/TEN

Конкурентная среда мирового рынка лечения SJS/TEN содержит сведения по конкурентам. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в НИОКР, новых рыночных инициативах, производственных площадках и объектах, сильных и слабых сторонах компании, запуске продукта, одобрении продукта, широте и дыхании продукта, доминировании приложений и жизненно важной кривой типа продукта. Приведенные выше данные касаются только фокуса компании на мировом рынке лечения SJS/TEN.

Некоторые из основных игроков, работающих на мировом рынке лечения синдрома Стивенса-Джонсона/тенинового энцефалита, включают 3M (США), Cardinal Health (США), BD (США), Smith + Nephew (Великобритания), Novartis AG (Швейцария), Amneal Pharmaceuticals LLC. (США), Amgen Inc. (США), Pfizer Inc. (США), Colgate-Palmolive Company (США), Merck & Co., Inc. (США), Mölnlycke Health Care AB. (Швеция), Xttrium Laboratories (США), Schülke & Mayr GmbH (Германия), ICPA Health Products Ltd (Индия), Purdue Pharma LP (США), eugia (дочерняя компания Aurobindo Pharma) и AdvaCare Pharma (США) и другие.

SKU-70083

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Интерактивная панель анализа данных
Панель анализа компании для возможностей с высоким потенциалом роста
Доступ аналитика-исследователя для настройки и запросов
Анализ конкурентов с помощью интерактивной панели
Последние новости, обновления и анализ тенденций
Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов

Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL SJS/TEN TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 KEY TRENDS

4.2 COST OF TREATMENT

4.3 KEY PLAYERS STRATEGIES

4.4 LONG TERM GROWTH APPROACH

5 EPIDEMIOLOGY

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.2 DEMOGRAPHIC TRENDS

6.3 PATIENT FLOW DIAGRAM

6.4 KEY PRICING STRATEGIES

6.5 KEY PATIENT ENROLLMENT STRATEGIES

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN

7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT

7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN

7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT

7.2 RESTRAINTS

7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN

7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT

7.3 OPPORTUNITIES

7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN

7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT

7.4 CHALLENGES

7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN

7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT

8 GLOBAL SJS/TEN TREATMENT MARKET, BY TREATMENT

8.1 OVERVIEW

8.2 MEDICATIONS

8.2.1 ANTIHISTAMINES

8.2.1.1 HYDROXYZINE

8.2.1.2 FEXOFENADINE

8.2.2 CORTICOSTEROID

8.2.2.1 DEXAMETHASONE

8.2.2.2 PREDNISOLONE

8.2.2.3 METHYLPREDNISOLONE

8.2.2.4 HYDROCORTISONE

8.2.2.5 OTHERS

8.2.3 ANTIBIOTICS

8.2.3.1 NAFCILLIN

8.2.3.2 GENTAMICIN

8.2.3.3 OTHERS

8.2.4 ANALGESICS

8.2.4.1 MORPHINE

8.2.4.2 FENTANYL CITRATE

8.2.4.3 OTHERS

8.2.5 ANTICOAGULANTS

8.2.6 ANTISEPTICS

8.2.6.1 CHLORHEXIDINE GLUCONATE

8.2.6.1.1 PERIOGARD

8.2.6.1.2 PERIDEX

8.2.6.1.3 AVAGARD

8.2.6.1.4 HIBICLENS

8.2.6.1.5 OTHERS

8.2.6.2 OCTENISEPT

8.2.6.3 POLYHEXANIDE SOLUTIONS

8.2.6.4 OTHERS

8.2.7 INTRAVENOUS IMMUNOGLOBULIN

8.2.8 CYCLOSPORINE

8.2.8.1 NEORAL

8.2.8.2 SANDIMMUNE

8.2.8.3 OTHERS

8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)‒BLOCKING AGENT (ETANERCEPT)

8.2.10 OTHER TREATMENT

8.2.10.1 CYCLOPHOSPHAMIDE

8.2.10.2 N-ACETYLCYSTEINE

8.2.10.3 MONOCLONAL ANTIBODIES

8.2.10.4 THALIDOMIDE

8.3 SUPPORT CARE

8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES

8.3.2 PAIN MANAGEMENT

8.3.2.1 LIDOCAINE

8.3.2.2 OTHERS

8.3.3 NUTRITION SUPPORT

8.3.4 ORAL CARE

8.3.5 PLASMAPHERESIS

8.3.6 BANDAGES

8.3.6.1 BIOLOGICAL DRESSING

8.3.6.1.1 ALLOGRAFT

8.3.6.1.2 XENOGRAFT

8.3.6.1.3 HOMOGRAFT

8.3.6.1.4 OTHERS

8.3.6.2 BIOSYNTHETIC DRESSING

8.3.6.3 SILVER IMPREGNATED DRESSING

8.4 HOSPITALIZATION

8.5 ISOLATION

8.6 OINTMENTS

8.6.1 BENZOCAINE

8.6.2 AMERICAINE

8.6.3 ANBESOL

8.6.4 CHIGGEREX PLUS

8.6.5 OTHERS

8.7 OTHERS

9 GLOBAL SJS/TEN TREATMENT MARKET, BY DIAGNOSIS

9.1 OVERVIEW

9.2 PHYSICAL EXAM

9.3 SKIN BIOPSY

9.4 MEDICAL HISTORY

9.5 BLOOD TEST

9.5.1 COMPLETE BLOOD COUNT

9.5.2 ERYTHROCYTE SEDIMENTATION RATE

9.5.3 COAGULATION STUDIES

9.5.4 UREA AND ELECTROLYTES

9.5.5 LIVER FUNCTION TEST

9.6 CULTURES

9.7 OTHERS

10 GLOBAL SJS/TEN TREATMENT MARKET, BY CAUSE

10.1 OVERVIEW

10.2 SPECIFIC TREATMENT

10.3 INFECTION

10.4 OTHERS

11 GLOBAL SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.3 PARENTERAL

11.3.1 INTRAVENOUS

11.3.2 SUBCUTANEOUS

11.3.3 OTHERS

11.4 TOPICAL

11.4.1 OINTMENTS

11.4.2 SOLUTION

11.4.3 CREAMS

11.4.4 OTHERS

11.5 OTHERS

12 GLOBAL SJS/TEN TREATMENT MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 BRANDED

12.2.1 NEORAL

12.2.2 SANDIMMUNE

12.2.3 VISTARIL

12.2.4 DURAMORPH

12.2.5 FENTORA

12.2.6 ENBREL

12.2.7 OTHERS

12.3 GENERIC

13 GLOBAL SJS/TEN TREATMENT MARKET, BY THERAPY TYPE

13.1 OVERVIEW

13.2 COMBINATION THERAPY

13.3 MONOTHERAPY

14 GLOBAL SJS/TEN TREATMENT MARKET, BY PATIENT TYPE

14.1 OVERVIEW

14.2 GERIATRIC

14.2.1 FEMALE

14.2.2 MALE

14.3 ADULT

14.3.1 FEMALE

14.3.2 MALE

14.4 PEDIATRIC

15 GLOBAL SJS/TEN TREATMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 SPECIALTY CLINICS

15.4 AMBULATORY SURGICAL CENTER

15.5 HOMECARE SETTING

15.6 OTHERS

16 GLOBAL SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 RETAIL PHARMACIES

16.2.1 HOSPITAL ASSOCIATED PHARMACIES

16.2.2 DRUG STORE

16.2.3 ONLINE PHARMACIES

16.3 DIRECT TENDERS

16.4 OTHERS

17 GLOBAL SJS/TEN TREATMENT MARKET, BY REGION

17.1 OVERVIEW

17.2 NORTH AMERICA

17.2.1 U.S.

17.2.2 CANADA

17.2.3 MEXICO

17.3 SOUTH AMERICA

17.3.1 BRAZIL

17.3.2 ARGENTINA

17.3.3 REST OF SOUTH AMERICA

17.4 EUROPE

17.4.1 GERMANY

17.4.2 FRANCE

17.4.3 U.K.

17.4.4 ITALY

17.4.5 SPAIN

17.4.6 RUSSIA

17.4.7 TURKEY

17.4.8 BELGIUM

17.4.9 DENMARK

17.4.10 NETHERLANDS

17.4.11 SWITZERLAND

17.4.12 SWEDEN

17.4.13 POLAND

17.4.14 NORWAY

17.4.15 FINLAND

17.4.16 REST OF EUROPE

17.5 ASIA-PACIFIC

17.5.1 CHINA

17.5.2 JAPAN

17.5.3 INDIA

17.5.4 SOUTH KOREA

17.5.5 AUSTRALIA

17.5.6 SINGAPORE

17.5.7 THAILAND

17.5.8 INDONESIA

17.5.9 PHILIPPINES

17.5.10 MALAYSIA

17.5.11 NEW ZEALAND

17.5.12 VIETNAM

17.5.13 TAIWAN

17.5.14 REST OF ASIA-PACIFIC

17.6 MIDDLE EAST AND AFRICA

17.6.1 SOUTH AFRICA

17.6.2 SAUDI ARABIA

17.6.3 BAHRAIN

17.6.4 U.A.E

17.6.5 KUWAIT

17.6.6 OMAN

17.6.7 QATAR

17.6.8 EGYPT

17.6.9 ISRAEL

17.6.10 REST OF MIDDLE EAST AND AFRICA

18 GLOBAL SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: GLOBAL

18.2 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18.3 COMPANY SHARE ANALYSIS: NORTH AMERICA

18.4 COMPANY SHARE ANALYSIS: EUROPE

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 PFIZER INC.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENT

20.2 NOVARTIS AG

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENT

20.3 MERCK & CO., INC.

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENT

20.4 AMNEAL PHARMACEUTICAL LLC.

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENT

20.5 AMGEN INC.

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 PRODUCT PORTFOLIO

20.5.4 RECENT DEVELOPMENT

20.6 ADVACARE PHARMA

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.7 BD

20.7.1 COMPANY SNAPSHOT

20.7.2 REVENUE ANALYSIS

20.7.3 PRODUCT PORTFOLIO

20.7.4 RECENT DEVELOPMENT

20.8 CARDINAL HEALTH

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.9 COLGATE-PALMOLIVE COMPANY

20.9.1 COMPANY SNAPSHOT

20.9.2 REVENUE ANALYSIS

20.9.3 PRODUCT PORTFOLIO

20.9.4 RECENT DEVELOPMENT

20.1 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA)

20.10.1 COMPANY SNAPSHOT

20.10.2 REVENUE ANALYSIS

20.10.3 PRODUCT PORTFOLIO

20.10.4 RECENT DEVELOPMENT

20.11 ICPA HEALTH PRODUCTS LTD

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLIO

20.11.3 RECENT DEVELOPMENT

20.12 3M

20.12.1 COMPANY SNAPSHOT

20.12.2 REVENUE ANALYSIS

20.12.3 PRODUCT PORTFOLIO

20.12.4 RECENT DEVELOPMENT

20.13 MOLNLYCKE HEALTH CARE AB.

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.14 PURDUE PHARMA L.P.

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENT

20.15 SCHULKE & MAYR GMBH

20.15.1 COMPANY SNAPSHOT

20.15.2 PRODUCT PORTFOLIO

20.15.3 RECENT DEVELOPMENT

20.16 SMITH + NEPHEW

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENT

20.17 XTTRIUM LABORATORIES

20.17.1 COMPANY SNAPSHOT

20.17.2 PRODUCT PORTFOLIO

20.17.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

Список таблиц

TABLE 1 GLOBAL SJS/TEN TREATMENT MARKET, PATENT ANALYSIS

TABLE 2 GLOBAL SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 3 GLOBAL MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 GLOBAL MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 5 GLOBAL ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 6 GLOBAL CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 7 GLOBAL ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 8 GLOBAL ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 9 GLOBAL ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 10 GLOBAL CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 11 GLOBAL CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 12 GLOBAL OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 13 GLOBAL SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 GLOBAL SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 15 GLOBAL PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 16 GLOBAL BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 17 GLOBAL BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 18 GLOBAL HOSPITALIZATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 GLOBAL ISOLATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 GLOBAL OINTMENTS IN JS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 GLOBAL OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 22 GLOBAL OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 GLOBAL SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 24 GLOBAL PHYSICAL EXAM IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 GLOBAL SKIN BIOPSY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 GLOBAL MEDICAL HISTORY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 GLOBAL BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 GLOBAL BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 29 GLOBAL CULTURES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 GLOBAL OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 GLOBAL SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 32 GLOBAL SPECIFIC TREATMENT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 GLOBAL INFECTION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 GLOBAL OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 GLOBAL SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 36 GLOBAL ORAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 GLOBAL PARENTERAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 GLOBAL PARENTERAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 39 GLOBAL TOPICAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 GLOBAL TOPICAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 41 GLOBAL OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 GLOBAL SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 43 GLOBAL BRANDED IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 GLOBAL BRANDED IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 45 GLOBAL GENERIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 GLOBAL SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 47 GLOBAL COMBINATION THERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 GLOBAL MONOTHERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 GLOBAL SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 50 GLOBAL GERAITRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 GLOBAL GERIATRIC IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 52 GLOBAL ADULT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 GLOBAL ADULT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 54 GLOBAL PEDIATRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 GLOBAL SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 56 GLOBAL HOSPITALS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 GLOBAL SPECIALTY CLINICS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 58 GLOBAL AMBULATORY SURGICAL CENTER IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 GLOBAL HOMECARE SETTING IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 GLOBAL OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 GLOBAL SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 62 GLOBAL RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 GLOBAL RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 64 GLOBAL DIRECT TENDERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 65 GLOBAL OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 GLOBAL SJS/TEN TREATMENT MARKET, BY REGION, 2023-2030 (USD MILLION)

TABLE 67 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 68 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 75 NORTH AMERICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 76 NORTH AMERICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 77 NORTH AMERICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 78 NORTH AMERICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 79 NORTH AMERICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 80 NORTH AMERICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 81 NORTH AMERICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 82 NORTH AMERICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 83 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 84 NORTH AMERICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 85 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 86 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 87 NORTH AMERICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 88 NORTH AMERICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 89 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 90 NORTH AMERICA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 91 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 92 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 93 NORTH AMERICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 94 NORTH AMERICA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 95 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 96 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 97 NORTH AMERICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 98 U.S. SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 99 U.S. MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 100 U.S. ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 101 U.S. CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 102 U.S. ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 103 U.S. ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 104 U.S. ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 105 U.S. CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 106 U.S. CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 107 U.S. OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 108 U.S. SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 109 U.S. PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 110 U.S. BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 111 U.S. BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 112 U.S. OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 113 U.S. SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 114 U.S. BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 115 U.S. SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 116 U.S. SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 117 U.S. PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 118 U.S. TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 119 U.S. SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 120 U.S. BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 121 U.S. SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 122 U.S. SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 123 U.S. GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 124 U.S. ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 125 U.S. SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 126 U.S. SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 127 U.S. RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 128 CANADA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 129 CANADA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 130 CANADA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 131 CANADA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 132 CANADA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 133 CANADA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 134 CANADA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 135 CANADA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 136 CANADA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 137 CANADA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 138 CANADA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 139 CANADA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 140 CANADA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 141 CANADA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 142 CANADA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 143 CANADA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 144 CANADA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 145 CANADA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 146 CANADA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 147 CANADA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 148 CANADA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 149 CANADA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 150 CANADA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 151 CANADA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 152 CANADA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 153 CANADA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 154 CANADA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 155 CANADA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 156 CANADA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 157 CANADA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 158 MEXICO SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 159 MEXICO MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 160 MEXICO ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 161 MEXICO CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 162 MEXICO ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 163 MEXICO ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 164 MEXICO ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 165 MEXICO CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 166 MEXICO CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 167 MEXICO OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 168 MEXICO SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 169 MEXICO PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 170 MEXICO BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 171 MEXICO BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 172 MEXICO OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 173 MEXICO SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 174 MEXICO BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 175 MEXICO SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 176 MEXICO SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 177 MEXICO PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 178 MEXICO TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 179 MEXICO SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 180 MEXICO BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 181 MEXICO SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 182 MEXICO SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 183 MEXICO GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 184 MEXICO ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 185 MEXICO SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 186 MEXICO SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 187 MEXICO RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 188 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 189 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 190 SOUTH AMERICA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 191 SOUTH AMERICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 192 SOUTH AMERICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 193 SOUTH AMERICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 194 SOUTH AMERICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 195 SOUTH AMERICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 196 SOUTH AMERICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 197 SOUTH AMERICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 198 SOUTH AMERICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 199 SOUTH AMERICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 200 SOUTH AMERICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 201 SOUTH AMERICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 202 SOUTH AMERICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 203 SOUTH AMERICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 204 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 205 SOUTH AMERICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 206 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 207 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 208 SOUTH AMERICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 209 SOUTH AMERICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 210 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 211 SOUTH AMERICA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 212 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 213 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 214 SOUTH AMERICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 215 SOUTH AMERICA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 216 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 217 SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 218 SOUTH AMERICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 219 BRAZIL SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 220 BRAZIL MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 221 BRAZIL ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 222 BRAZIL CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 223 BRAZIL ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 224 BRAZIL ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 225 BRAZIL ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 226 BRAZIL CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 227 BRAZIL CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 228 BRAZIL OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 229 BRAZIL SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 230 BRAZIL PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 231 BRAZIL BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 232 BRAZIL BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 233 BRAZIL OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 234 BRAZIL SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 235 BRAZIL BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 236 BRAZIL SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 237 BRAZIL SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 238 BRAZIL PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 239 BRAZIL TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 240 BRAZIL SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 241 BRAZIL BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 242 BRAZIL SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 243 BRAZIL SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 244 BRAZIL GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 245 BRAZIL ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 246 BRAZIL SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 247 BRAZIL SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 248 BRAZIL RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 249 ARGENTINA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 250 ARGENTINA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 251 ARGENTINA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 252 ARGENTINA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 253 ARGENTINA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 254 ARGENTINA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 255 ARGENTINA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 256 ARGENTINA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 257 ARGENTINA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 258 ARGENTINA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 259 ARGENTINA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 260 ARGENTINA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 261 ARGENTINA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 262 ARGENTINA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 263 ARGENTINA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 264 ARGENTINA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 265 ARGENTINA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 266 ARGENTINA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 267 ARGENTINA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 268 ARGENTINA PRENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 269 ARGENTINA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 270 ARGENTINA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 271 ARGENTINA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 272 ARGENTINA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 273 ARGENTINA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 274 ARGENTINA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 275 ARGENTINA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 276 ARGENTINA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 277 ARGENTINA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 278 ARGENTINA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 279 REST OF SOUTH AMERICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 280 EUROPE SJS/TEN TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 281 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 282 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 283 EUROPE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 284 EUROPE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 285 EUROPE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 286 EUROPE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 287 EUROPE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 288 EUROPE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 289 EUROPE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 290 EUROPE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 291 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 292 EUROPE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 293 EUROPE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 294 EUROPE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 295 EUROPE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 296 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 297 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 298 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 299 EUROPE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 300 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 301 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 302 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 303 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 304 EUROPE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 305 EUROPE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 306 EUROPE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 307 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 308 EUROPE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 309 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 310 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 311 GERMANY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 312 GERMANY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 313 GERMANY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 314 GERMANY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 315 GERMANY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 316 GERMANY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 317 GERMANY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 318 GERMANY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 319 GERMANY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 320 GERMANY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 321 GERMANY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 322 GERMANY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 323 GERMANY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 324 GERMANY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 325 GERMANY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 326 GERMANY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 327 GERMANY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 328 GERMANY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 329 GERMANY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 330 GERMANY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 331 GERMANY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 332 GERMANY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 333 GERMANY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 334 GERMANY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 335 GERMANY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 336 GERMANY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 337 GERMANY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 338 GERMANY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 339 GERMANY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 340 GERMANY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 341 FRANCE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 342 FRANCE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 343 FRANCE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 344 FRANCE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 345 FRANCE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 346 FRANCE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 347 FRANCE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 348 FRANCE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 349 FRANCE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 350 FRANCE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 351 FRANCE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 352 FRANCE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 353 FRANCE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 354 FRANCE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 355 FRANCE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 356 FRANCE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 357 FRANCE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 358 FRANCE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 359 FRANCE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 360 FRANCE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 361 FRANCE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 362 FRANCE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 363 FRANCE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 364 FRANCE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 365 FRANCE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 366 FRANCE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 367 FRANCE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 368 FRANCE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 369 FRANCE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 370 FRANCE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 371 U.K. SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 372 U.K. MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 373 U.K. ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 374 U.K. CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 375 U.K. ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 376 U.K. ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 377 U.K. ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 378 U.K. CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 379 U.K. CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 380 U.K. OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 381 U.K. SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 382 U.K. PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 383 U.K. BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 384 U.K. BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 385 U.K. OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 386 U.K. SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 387 U.K. BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 388 U.K. SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 389 U.K. SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 390 U.K. PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 391 U.K. TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 392 U.K. SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 393 U.K. BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 394 U.K. SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 395 U.K. SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 396 U.K. GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 397 U.K. ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 398 U.K. SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 399 U.K. SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 400 U.K. RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 401 ITALY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 402 ITALY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 403 ITALY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 404 ITALY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 405 ITALY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 406 ITALY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 407 ITALY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 408 ITALY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 409 ITALY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 410 ITALY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 411 ITALY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 412 ITALY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 413 ITALY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 414 ITALY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 415 ITALY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 416 ITALY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 417 ITALY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 418 ITALY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 419 ITALY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 420 ITALY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 421 ITALY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 422 ITALY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 423 ITALY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 424 ITALY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 425 ITALY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 426 ITALY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 427 ITALY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 428 ITALY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 429 ITALY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 430 ITALY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 431 SPAIN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 432 SPAIN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 433 SPAIN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 434 SPAIN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 435 SPAIN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 436 SPAIN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 437 SPAIN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 438 SPAIN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 439 SPAIN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 440 SPAIN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 441 SPAIN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 442 SPAIN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 443 SPAIN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 444 SPAIN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 445 SPAIN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 446 SPAIN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 447 SPAIN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 448 SPAIN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 449 SPAIN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 450 SPAIN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 451 SPAIN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 452 SPAIN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 453 SPAIN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 454 SPAIN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 455 SPAIN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 456 SPAIN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 457 SPAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 458 SPAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 459 SPAIN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 460 RUSSIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 461 RUSSIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 462 RUSSIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 463 RUSSIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 464 RUSSIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 465 RUSSIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 466 RUSSIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 467 RUSSIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 468 RUSSIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 469 RUSSIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 470 RUSSIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 471 RUSSIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 472 RUSSIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 473 RUSSIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 474 RUSSIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 475 RUSSIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 476 RUSSIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 477 RUSSIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 478 RUSSIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 479 RUSSIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 480 RUSSIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 481 RUSSIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 482 RUSSIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 483 RUSSIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 484 RUSSIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 485 RUSSIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 486 RUSSIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 487 RUSSIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 488 RUSSIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 489 RUSSIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 490 TURKEY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 491 TURKEY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 492 TURKEY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 493 TURKEY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 494 TURKEY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 495 TURKEY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 496 TURKEY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 497 TURKEY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 498 TURKEY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 499 TURKEY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 500 TURKEY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 501 TURKEY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 502 TURKEY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 503 TURKEY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 504 TURKEY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 505 TURKEY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 506 TURKEY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 507 TURKEY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 508 TURKEY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 509 TURKEY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 510 TURKEY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 511 TURKEY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 512 TURKEY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 513 TURKEY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 514 TURKEY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 515 TURKEY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 516 TURKEY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 517 TURKEY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 518 TURKEY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 519 TURKEY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 520 BELGIUM SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 521 BELGIUM MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 522 BELGIUM ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 523 BELGIUM CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 524 BELGIUM ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 525 BELGIUM ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 526 BELGIUM ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 527 BELGIUM CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 528 BELGIUM CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 529 BELGIUM OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 530 BELGIUM SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 531 BELGIUM PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 532 BELGIUM BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 533 BELGIUM BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 534 BELGIUM OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 535 BELGIUM SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 536 BELGIUM BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 537 BELGIUM SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 538 BELGIUM SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 539 BELGIUM PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 540 BELGIUM TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 541 BELGIUM SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 542 BELGIUM BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 543 BELGIUM SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 544 BELGIUM SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 545 BELGIUM GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 546 BELGIUM ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 547 BELGIUM SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 548 BELGIUM SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 549 BELGIUM RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 550 DENMARK SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 551 DENMARK MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 552 DENMARK ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 553 DENMARK CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 554 DENMARK ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 555 DENMARK ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 556 DENMARK ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 557 DENMARK CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 558 DENMARK CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 559 DENMARK OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 560 DENMARK SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 561 DENMARK PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 562 DENMARK BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 563 DENMARK BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 564 DENMARK OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 565 DENMARK SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 566 DENMARK BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 567 DENMARK SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 568 DENMARK SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 569 DENMARK PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 570 DENMARK TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 571 DENMARK SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 572 DENMARK BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 573 DENMARK SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 574 DENMARK SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 575 DENMARK GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 576 DENMARK ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 577 DENMARK SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 578 DENMARK SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 579 DENMARK RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 580 NETHERLANDS SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 581 NETHERLANDS MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 582 NETHERLANDS ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 583 NETHERLANDS CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 584 NETHERLANDS ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 585 NETHERLANDS ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 586 NETHERLANDS ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 587 NETHERLANDS CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 588 NETHERLANDS CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 589 NETHERLANDS OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 590 NETHERLANDS SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 591 NETHERLANDS PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 592 NETHERLANDS BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 593 NETHERLANDS BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 594 NETHERLANDS OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 595 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 596 NETHERLANDS BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 597 NETHERLANDS SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 598 NETHERLANDS SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 599 NETHERLANDS PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 600 NETHERLANDS TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 601 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 602 NETHERLANDS BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 603 NETHERLANDS SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 604 NETHERLANDS SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 605 NETHERLANDS GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 606 NETHERLANDS ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 607 NETHERLANDS SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 608 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 609 NETHERLANDS RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 610 SWITZERLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 611 SWITZERLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 612 SWITZERLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 613 SWITZERLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 614 SWITZERLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 615 SWITZERLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 616 SWITZERLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 617 SWITZERLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 618 SWITZERLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 619 SWITZERLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 620 SWITZERLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 621 SWITZERLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 622 SWITZERLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 623 SWITZERLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 624 SWITZERLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 625 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 626 SWITZERLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 627 SWITZERLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 628 SWITZERLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 629 SWITZERLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 630 SWITZERLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 631 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 632 SWITZERLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 633 SWITZERLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 634 SWITZERLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 635 SWITZERLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 636 SWITZERLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 637 SWITZERLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 638 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 639 SWITZERLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 640 SWEDEN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 641 SWEDEN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 642 SWEDEN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 643 SWEDEN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 644 SWEDEN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 645 SWEDEN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 646 SWEDEN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 647 SWEDEN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 648 SWEDEN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 649 SWEDEN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 650 SWEDEN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 651 SWEDEN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 652 SWEDEN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 653 SWEDEN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 654 SWEDEN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 655 SWEDEN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 656 SWEDEN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 657 SWEDEN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 658 SWEDEN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 659 SWEDEN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 660 SWEDEN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 661 SWEDEN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 662 SWEDEN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 663 SWEDEN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 664 SWEDEN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 665 SWEDEN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 666 SWEDEN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 667 SWEDEN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 668 SWEDEN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 669 SWEDEN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 670 POLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 671 POLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 672 POLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 673 POLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 674 POLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 675 POLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 676 POLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 677 POLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 678 POLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 679 POLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 680 POLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 681 POLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 682 POLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 683 POLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 684 POLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 685 POLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 686 POLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 687 POLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 688 POLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 689 POLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 690 POLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 691 POLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 692 POLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 693 POLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 694 POLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 695 POLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 696 POLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 697 POLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 698 POLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 699 POLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 700 NORWAY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 701 NORWAY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 702 NORWAY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 703 NORWAY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 704 NORWAY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 705 NORWAY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 706 NORWAY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 707 NORWAY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 708 NORWAY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 709 NORWAY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 710 NORWAY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 711 NORWAY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 712 NORWAY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 713 NORWAY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 714 NORWAY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 715 NORWAY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 716 NORWAY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 717 NORWAY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 718 NORWAY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 719 NORWAY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 720 NORWAY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 721 NORWAY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 722 NORWAY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 723 NORWAY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 724 NORWAY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 725 NORWAY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 726 NORWAY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 727 NORWAY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 728 NORWAY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 729 NORWAY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 730 FINLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 731 FINLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 732 FINLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 733 FINLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 734 FINLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 735 FINLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 736 FINLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 737 FINLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 738 FINLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 739 FINLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 740 FINLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 741 FINLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 742 FINLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 743 FINLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 744 FINLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 745 FINLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 746 FINLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 747 FINLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 748 FINLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 749 FINLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 750 FINLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 751 FINLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 752 FINLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 753 FINLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 754 FINLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 755 FINLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 756 FINLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 757 FINLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 758 FINLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 759 FINLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 760 REST OF EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 761 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 762 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 763 ASIA-PACIFIC MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 764 ASIA-PACIFIC ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 765 ASIA-PACIFIC CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 766 ASIA-PACIFIC ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 767 ASIA-PACIFIC ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 768 ASIA-PACIFIC ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 769 ASIA-PACIFIC CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 770 ASIA-PACIFIC CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 771 ASIA-PACIFIC OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 772 ASIA-PACIFIC SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 773 ASIA-PACIFIC PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 774 ASIA-PACIFIC BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 775 ASIA-PACIFIC BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 776 ASIA-PACIFIC OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 777 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 778 ASIA-PACIFIC BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 779 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 780 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 781 ASIA-PACIFIC PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 782 ASIA-PACIFIC TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 783 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 784 ASIA-PACIFIC BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 785 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 786 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 787 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 788 ASIA-PACIFIC ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 789 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 790 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 791 ASIA-PACIFIC RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 792 CHINA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 793 CHINA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 794 CHINA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 795 CHINA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 796 CHINA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 797 CHINA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 798 CHINA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 799 CHINA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 800 CHINA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 801 CHINA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 802 CHINA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 803 CHINA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 804 CHINA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 805 CHINA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 806 CHINA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 807 CHINA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 808 CHINA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 809 CHINA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 810 CHINA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 811 CHINA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 812 CHINA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 813 CHINA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 814 CHINA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 815 CHINA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 816 CHINA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 817 CHINA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 818 CHINA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 819 CHINA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 820 CHINA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 821 CHINA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 822 JAPAN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 823 JAPAN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 824 JAPAN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 825 JAPAN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 826 JAPAN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 827 JAPAN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 828 JAPAN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 829 JAPAN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 830 JAPAN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 831 JAPAN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 832 JAPAN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 833 JAPAN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 834 JAPAN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 835 JAPAN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 836 JAPAN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 837 JAPAN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 838 JAPAN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 839 JAPAN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 840 JAPAN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 841 JAPAN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 842 JAPAN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 843 JAPAN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 844 JAPAN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 845 JAPAN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 846 JAPAN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 847 JAPAN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 848 JAPAN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 849 JAPAN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 850 JAPAN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 851 JAPAN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 852 INDIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 853 INDIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 854 INDIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 855 INDIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 856 INDIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 857 INDIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 858 INDIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 859 INDIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 860 INDIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 861 INDIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 862 INDIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 863 INDIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 864 INDIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 865 INDIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 866 INDIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 867 INDIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 868 INDIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 869 INDIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 870 INDIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 871 INDIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 872 INDIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 873 INDIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 874 INDIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 875 INDIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 876 INDIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 877 INDIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 878 INDIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 879 INDIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 880 INDIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 881 INDIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 882 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 883 SOUTH KOREA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 884 SOUTH KOREA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 885 SOUTH KOREA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 886 SOUTH KOREA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 887 SOUTH KOREA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 888 SOUTH KOREA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 889 SOUTH KOREA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 890 SOUTH KOREA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 891 SOUTH KOREA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 892 SOUTH KOREA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 893 SOUTH KOREA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 894 SOUTH KOREA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 895 SOUTH KOREA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 896 SOUTH KOREA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 897 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 898 SOUTH KOREA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 899 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 900 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 901 SOUTH KOREA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 902 SOUTH KOREA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 903 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 904 SOUTH KOREA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 905 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 906 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 907 SOUTH KOREA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 908 SOUTH KOREA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 909 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 910 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 911 SOUTH KOREA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 912 AUSTRALIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 913 AUSTRALIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 914 AUSTRALIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 915 AUSTRALIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 916 AUSTRALIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 917 AUSTRALIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 918 AUSTRALIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 919 AUSTRALIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 920 AUSTRALIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 921 AUSTRALIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 922 AUSTRALIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 923 AUSTRALIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 924 AUSTRALIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 925 AUSTRALIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 926 AUSTRALIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 927 AUSTRALIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 928 AUSTRALIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 929 AUSTRALIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 930 AUSTRALIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 931 AUSTRALIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 932 AUSTRALIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 933 AUSTRALIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 934 AUSTRALIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 935 AUSTRALIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 936 AUSTRALIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 937 AUSTRALIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 938 AUSTRALIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 939 AUSTRALIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 940 AUSTRALIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 941 AUSTRALIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 942 SINGAPORE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 943 SINGAPORE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 944 SINGAPORE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 945 SINGAPORE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 946 SINGAPORE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 947 SINGAPORE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 948 SINGAPORE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 949 SINGAPORE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 950 SINGAPORE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 951 SINGAPORE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 952 SINGAPORE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 953 SINGAPORE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 954 SINGAPORE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 955 SINGAPORE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 956 SINGAPORE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 957 SINGAPORE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 958 SINGAPORE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 959 SINGAPORE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 960 SINGAPORE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 961 SINGAPORE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 962 SINGAPORE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 963 SINGAPORE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 964 SINGAPORE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 965 SINGAPORE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 966 SINGAPORE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 967 SINGAPORE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 968 SINGAPORE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 969 SINGAPORE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 970 SINGAPORE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 971 SINGAPORE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 972 THAILAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 973 THAILAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 974 THAILAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 975 THAILAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 976 THAILAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 977 THAILAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 978 THAILAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 979 THAILAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 980 THAILAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 981 THAILAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 982 THAILAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 983 THAILAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 984 THAILAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 985 THAILAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 986 THAILAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 987 THAILAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 988 THAILAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 989 THAILAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 990 THAILAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 991 THAILAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 992 THAILAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 993 THAILAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 994 THAILAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 995 THAILAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 996 THAILAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 997 THAILAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 998 THAILAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 999 THAILAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1000 THAILAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1001 THAILAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1002 INDONESIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1003 INDONESIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1004 INDONESIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1005 INDONESIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1006 INDONESIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1007 INDONESIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1008 INDONESIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1009 INDONESIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1010 INDONESIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1011 INDONESIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1012 INDONESIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1013 INDONESIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1014 INDONESIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1015 INDONESIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1016 INDONESIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1017 INDONESIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1018 INDONESIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1019 INDONESIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1020 INDONESIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1021 INDONESIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1022 INDONESIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1023 INDONESIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1024 INDONESIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1025 INDONESIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1026 INDONESIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1027 INDONESIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1028 INDONESIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1029 INDONESIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1030 INDONESIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1031 INDONESIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1032 PHILIPPINES SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1033 PHILIPPINES MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1034 PHILIPPINES ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1035 PHILIPPINES CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1036 PHILIPPINES ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1037 PHILIPPINES ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1038 PHILIPPINES ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1039 PHILIPPINES CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1040 PHILIPPINES CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1041 PHILIPPINES OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1042 PHILIPPINES SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1043 PHILIPPINES PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1044 PHILIPPINES BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1045 PHILIPPINES BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1046 PHILIPPINES OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1047 PHILIPPINES SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1048 PHILIPPINES BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1049 PHILIPPINES SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1050 PHILIPPINES SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1051 PHILIPPINES PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1052 PHILIPPINES TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1053 PHILIPPINES SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1054 PHILIPPINES BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1055 PHILIPPINES SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1056 PHILIPPINES SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1057 PHILIPPINES GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1058 PHILIPPINES ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1059 PHILIPPINES SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1060 PHILIPPINES SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1061 PHILIPPINES RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1062 MALAYSIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1063 MALAYSIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1064 MALAYSIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1065 MALAYSIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1066 MALAYSIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1067 MALAYSIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1068 MALAYSIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1069 MALAYSIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1070 MALAYSIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1071 MALAYSIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1072 MALAYSIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1073 MALAYSIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1074 MALAYSIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1075 MALAYSIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1076 MALAYSIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1077 MALAYSIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1078 MALAYSIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1079 MALAYSIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1080 MALAYSIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1081 MALAYSIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1082 MALAYSIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1083 MALAYSIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1084 MALAYSIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1085 MALAYSIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1086 MALAYSIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1087 MALAYSIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1088 MALAYSIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1089 MALAYSIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1090 MALAYSIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1091 MALAYSIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1092 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1093 NEW ZEALAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1094 NEW ZEALAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1095 NEW ZEALAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1096 NEW ZEALAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1097 NEW ZEALAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1098 NEW ZEALAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1099 NEW ZEALAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1100 NEW ZEALAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1101 NEW ZEALAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1102 NEW ZEALAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1103 NEW ZEALAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1104 NEW ZEALAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1105 NEW ZEALAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1106 NEW ZEALAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1107 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1108 NEW ZEALAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1109 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1110 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1111 NEW ZEALAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1112 NEW ZEALAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1113 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1114 NEW ZEALAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1115 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1116 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1117 NEW ZEALAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1118 NEW ZEALAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1119 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1120 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1121 NEW ZEALAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1122 VIETNAM SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1123 VIETNAM MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1124 VIETNAM ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1125 VIETNAM CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1126 VIETNAM ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1127 VIETNAM ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1128 VIETNAM ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1129 VIETNAM CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1130 VIETNAM CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1131 VIETNAM OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1132 VIETNAM SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1133 VIETNAM PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1134 VIETNAM BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1135 VIETNAM BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1136 VIETNAM OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1137 VIETNAM SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1138 VIETNAM BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1139 VIETNAM SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1140 VIETNAM SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1141 VIETNAM PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1142 VIETNAM TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1143 VIETNAM SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1144 VIETNAM BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1145 VIETNAM SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1146 VIETNAM SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1147 VIETNAM GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1148 VIETNAM ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1149 VIETNAM SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1150 VIETNAM SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1151 VIETNAM RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1152 TAIWAN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1153 TAIWAN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1154 TAIWAN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1155 TAIWAN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1156 TAIWAN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1157 TAIWAN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1158 TAIWAN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1159 TAIWAN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1160 TAIWAN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1161 TAIWAN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1162 TAIWAN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1163 TAIWAN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1164 TAIWAN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1165 TAIWAN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1166 TAIWAN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1167 TAIWAN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1168 TAIWAN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1169 TAIWAN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1170 TAIWAN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1171 TAIWAN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1172 TAIWAN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1173 TAIWAN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1174 TAIWAN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1175 TAIWAN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1176 TAIWAN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1177 TAIWAN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1178 TAIWAN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1179 TAIWAN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1180 TAIWAN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1181 TAIWAN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1182 REST OF ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1183 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1184 MIDDLE EAST AND AFRICA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1185 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1186 MIDDLE EAST AND AFRICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1187 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1188 MIDDLE EAST AND AFRICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1189 MIDDLE EAST AND AFRICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1190 MIDDLE EAST AND AFRICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1191 MIDDLE EAST AND AFRICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1192 MIDDLE EAST AND AFRICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1193 MIDDLE EAST AND AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1194 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1195 MIDDLE EAST AND AFRICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1196 MIDDLE EAST AND AFRICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1197 MIDDLE EAST AND AFRICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1198 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1199 MIDDLE EAST AND AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1200 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1201 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1202 MIDDLE EAST AND AFRICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1203 MIDDLE EAST AND AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1204 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1205 MIDDLE EAST AND AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1206 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1207 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1208 MIDDLE EAST AND AFRICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1209 MIDDLE EAST AND AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1210 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1211 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1212 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1213 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1214 SOUTH AFRICA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1215 SOUTH AFRICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1216 SOUTH AFRICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1217 SOUTH AFRICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1218 SOUTH AFRICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1219 SOUTH AFRICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1220 SOUTH AFRICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1221 SOUTH AFRICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1222 SOUTH AFRICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1223 SOUTH AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1224 SOUTH AFRICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1225 SOUTH AFRICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1226 SOUTH AFRICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1227 SOUTH AFRICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1228 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1229 SOUTH AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1230 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1231 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1232 SOUTH AFRICA PRENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1233 SOUTH AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1234 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1235 SOUTH AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1236 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1237 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1238 SOUTH AFRICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1239 SOUTH AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1240 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1241 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1242 SOUTH AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1243 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1244 SAUDI ARABIA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1245 SAUDI ARABIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1246 SAUDI ARABIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1247 SAUDI ARABIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1248 SAUDI ARABIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1249 SAUDI ARABIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1250 SAUDI ARABIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1251 SAUDI ARABIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1252 SAUDI ARABIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1253 SAUDI ARABIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1254 SAUDI ARABIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1255 SAUDI ARABIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1256 SAUDI ARABIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1257 SAUDI ARABIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1258 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1259 SAUDI ARABIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1260 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1261 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1262 SAUDI ARABIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1263 SAUDI ARABIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1264 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1265 SAUDI ARABIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1266 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1267 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1268 SAUDI ARABIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1269 SAUDI ARABIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1270 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1271 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1272 SAUDI ARABIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1273 BAHRAIN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1274 BAHRAIN MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1275 BAHRAIN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1276 BAHRAIN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1277 BAHRAIN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1278 BAHRAIN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1279 BAHRAIN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1280 BAHRAIN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1281 BAHRAIN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1282 BAHRAIN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1283 BAHRAIN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1284 BAHRAIN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1285 BAHRAIN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1286 BAHRAIN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1287 BAHRAIN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1288 BAHRAIN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1289 BAHRAIN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1290 BAHRAIN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1291 BAHRAIN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1292 BAHRAIN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1293 BAHRAIN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1294 BAHRAIN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1295 BAHRAIN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1296 BAHRAIN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1297 BAHRAIN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1298 BAHRAIN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1299 BAHRAIN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1300 BAHRAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1301 BAHRAIN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1302 BAHRAIN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1303 U.A.E SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1304 U.A.E MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1305 U.A.E ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1306 U.A.E CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1307 U.A.E ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1308 U.A.E ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1309 U.A.E ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1310 U.A.E CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1311 U.A.E CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1312 U.A.E OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1313 U.A.E SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1314 U.A.E PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1315 U.A.E BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1316 U.A.E BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1317 U.A.E OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1318 U.A.E SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1319 U.A.E BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1320 U.A.E SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1321 U.A.E SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1322 U.A.E PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1323 U.A.E TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1324 U.A.E SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1325 U.A.E BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1326 U.A.E SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1327 U.A.E SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1328 U.A.E GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1329 U.A.E ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1330 U.A.E SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1331 U.A.E SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1332 U.A.E RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1333 KUWAIT SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1334 KUWAIT MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1335 KUWAIT ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1336 KUWAIT CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1337 KUWAIT ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1338 KUWAIT ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1339 KUWAIT ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1340 KUWAIT CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1341 KUWAIT CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1342 KUWAIT OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1343 KUWAIT SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1344 KUWAIT PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1345 KUWAIT BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1346 KUWAIT BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1347 KUWAIT OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1348 KUWAIT SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1349 KUWAIT BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1350 KUWAIT SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1351 KUWAIT SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1352 KUWAIT PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1353 KUWAIT TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1354 KUWAIT SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1355 KUWAIT BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1356 KUWAIT SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1357 KUWAIT SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1358 KUWAIT GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1359 KUWAIT ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1360 KUWAIT SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1361 KUWAIT SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1362 KUWAIT RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1363 OMAN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1364 OMAN MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1365 OMAN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1366 OMAN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1367 OMAN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1368 OMAN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1369 OMAN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1370 OMAN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1371 OMAN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1372 OMAN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1373 OMAN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1374 OMAN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1375 OMAN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1376 OMAN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1377 OMAN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1378 OMAN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1379 OMAN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1380 OMAN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1381 OMAN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1382 OMAN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1383 OMAN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1384 OMAN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1385 OMAN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1386 OMAN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1387 OMAN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1388 OMAN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1389 OMAN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1390 OMAN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1391 OMAN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1392 OMAN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1393 QATAR SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1394 QATAR MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1395 QATAR ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1396 QATAR CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1397 QATAR ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1398 QATAR ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1399 QATAR ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1400 QATAR CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1401 QATAR CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1402 QATAR OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1403 QATAR SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1404 QATAR PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1405 QATAR BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1406 QATAR BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1407 QATAR OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1408 QATAR SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1409 QATAR BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1410 QATAR SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1411 QATAR SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1412 QATAR PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1413 QATAR TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1414 QATAR SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1415 QATAR BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1416 QATAR SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1417 QATAR SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1418 QATAR GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1419 QATAR ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1420 QATAR SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1421 QATAR SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1422 QATAR RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1423 EGYPT SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1424 EGYPT MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1425 EGYPT ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1426 EGYPT CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1427 EGYPT ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1428 EGYPT ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1429 EGYPT ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1430 EGYPT CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1431 EGYPT CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1432 EGYPT OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1433 EGYPT SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1434 EGYPT PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1435 EGYPT BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1436 EGYPT BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1437 EGYPT OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1438 EGYPT SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1439 EGYPT BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1440 EGYPT SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1441 EGYPT SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1442 EGYPT PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1443 EGYPT TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1444 EGYPT SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1445 EGYPT BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1446 EGYPT SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1447 EGYPT SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1448 EGYPT GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1449 EGYPT ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1450 EGYPT SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1451 EGYPT SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1452 EGYPT RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1453 ISRAEL SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1454 ISRAEL MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1455 ISRAEL ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1456 ISRAEL CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1457 ISRAEL ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1458 ISRAEL ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1459 ISRAEL ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1460 ISRAEL CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1461 ISRAEL CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1462 ISRAEL OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1463 ISRAEL SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1464 ISRAEL PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1465 ISRAEL BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1466 ISRAEL BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1467 ISRAEL OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 1468 ISRAEL SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1469 ISRAEL BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 1470 ISRAEL SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 1471 ISRAEL SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1472 ISRAEL PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1473 ISRAEL TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 1474 ISRAEL SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1475 ISRAEL BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 1476 ISRAEL SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 1477 ISRAEL SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 1478 ISRAEL GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1479 ISRAEL ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1480 ISRAEL SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 1481 ISRAEL SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1482 ISRAEL RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1483 REST OF MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

Список рисунков

FIGURE 1 GLOBAL SJS/TEN TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL SJS/TEN TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL SJS/TEN TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL SJS/TEN TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL SJS/TEN TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL SJS/TEN TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL SJS/TEN TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL SJS/TEN TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 GLOBAL SJS/TEN TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL SJS/TEN TREATMENT MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN ARE EXPECTED TO DRIVE THE GLOBAL SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD FROM 2023 TO 2030

FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 & 2030

FIGURE 13 ASIA-PACIFIC IS EXPECTED TO DOMINATE THE GLOBAL SJS/TEN TREATMENT MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2023 TO 2030

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR SJS/TEN TREATMENT MANUFACTURERS IN THE FORECAST PERIOD FROM 2023 TO 2030

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL SJS/TEN TREATMENT MARKET

FIGURE 16 GLOBAL SJS/TEN TREATMENT MARKET: BY TREATMENT, 2022

FIGURE 17 GLOBAL SJS/TEN TREATMENT MARKET: BY TREATMENT, 2023-2030 (USD MILLION)

FIGURE 18 GLOBAL SJS/TEN TREATMENT MARKET: BY TREATMENT, CAGR (2023-2030)

FIGURE 19 GLOBAL SJS/TEN TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 20 GLOBAL SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2022

FIGURE 21 GLOBAL SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION)

FIGURE 22 GLOBAL SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, CAGR (2023-2030)

FIGURE 23 GLOBAL SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, LIFELINE CURVE

FIGURE 24 GLOBAL SJS/TEN TREATMENT MARKET: BY CAUSE, 2022

FIGURE 25 GLOBAL SJS/TEN TREATMENT MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 26 GLOBAL SJS/TEN TREATMENT MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 27 GLOBAL SJS/TEN TREATMENT MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 28 GLOBAL SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 29 GLOBAL SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 30 GLOBAL SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 31 GLOBAL SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 32 GLOBAL SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2022

FIGURE 33 GLOBAL SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)

FIGURE 34 GLOBAL SJS/TEN TREATMENT MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 35 GLOBAL SJS/TEN TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 36 GLOBAL SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2022

FIGURE 37 GLOBAL SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2023-2030 (USD MILLION)

FIGURE 38 GLOBAL SJS/TEN TREATMENT MARKET: BY THERAPY AREA, CAGR (2023-2030)

FIGURE 39 GLOBAL SJS/TEN TREATMENT MARKET: BY THERAPY AREA, LIFELINE CURVE

FIGURE 40 GLOBAL SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2022

FIGURE 41 GLOBAL SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)

FIGURE 42 GLOBAL SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, CAGR (2023-2030)

FIGURE 43 GLOBAL SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 44 GLOBAL SJS/TEN TREATMENT MARKET: BY END USER, 2022

FIGURE 45 GLOBAL SJS/TEN TREATMENT MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 46 GLOBAL SJS/TEN TREATMENT MARKET: BY END USER, CAGR (2023-2030)

FIGURE 47 GLOBAL SJS/TEN TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 48 GLOBAL SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 49 GLOBAL SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 50 GLOBAL SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 51 GLOBAL SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 52 GLOBAL SJS/TEN TREATMENT MARKET : SNAPSHOT (2022)

FIGURE 53 GLOBAL SJS/TEN TREATMENT MARKET : BY REGION (2022)

FIGURE 54 GLOBAL SJS/TEN TREATMENT MARKET : BY REGION (2023 & 2030)

FIGURE 55 GLOBAL SJS/TEN TREATMENT MARKET : BY REGION (2022 & 2030)

FIGURE 56 GLOBAL SJS/TEN TREATMENT MARKET : BY TREATMENT (2023-2030)

FIGURE 57 NORTH AMERICA SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 58 NORTH AMERICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)

FIGURE 59 NORTH AMERICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 60 NORTH AMERICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 61 NORTH AMERICA SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)

FIGURE 62 SOUTH AMERICA SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 63 SOUTH AMERICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)

FIGURE 64 SOUTH AMERICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 65 SOUTH AMERICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 66 SOUTH AMERICA SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)

FIGURE 67 EUROPE SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 68 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)

FIGURE 69 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 70 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 71 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)

FIGURE 72 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 73 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)

FIGURE 74 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 75 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 76 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)

FIGURE 77 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 78 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)

FIGURE 79 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 80 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 81 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)

FIGURE 82 GLOBAL SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 83 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 84 NORTH AMERICA SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 85 EUROPE SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)

View Detailed Information

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

What are the primary segments covered in the Global Sjs Ten Treatment Market report?

The market is segmented based on Global SJS/TEN Treatment Market, By Treatment (Medications, Support care, Hospitalization, Isolation, Ointments and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures and Others), Cause (Specific Treatment, Infection and Others), Route of Administration (Oral, Parenteral, Topical and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting and Others), Distribution Channel (Retail Pharmacies, Direct Tender and Others) - Industry Trends and Forecast to 2030. .

What is the current market size of the Global Sjs Ten Treatment Market?

The Global Sjs Ten Treatment Market size was valued at USD 7100.00 USD Million in 2022.

What is the expected growth rate of the Global Sjs Ten Treatment Market?

The Global Sjs Ten Treatment Market is projected to grow at a CAGR of 7.6% during the forecast period of 2023 to 2030.

Who are the key players in the Global Sjs Ten Treatment Market?

The major players operating in the market include 3M, Cardinal Health, BD, Smith + Nephew, Novartis AG, Amneal Pharmaceuticals, Amgen , Pfizer , Colgate, Palmolive Company, Merck & Co., Mölnlycke Health Care, Xttrium Laboratories, Schülke & Mayr GmbH, ICPA Health Products Ltd, Purdue Pharma L.P., Eugia, AdvaCare Pharma.

Which countries are analyzed in the Global Sjs Ten Treatment Market report?

The market report covers data from the U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Denmark, Switzerland, Sweden, Poland, Norway, Finland, Belgium, Turkey, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Indonesia, Philippines, Thailand,  Malaysia, Singapore, Vietnam, Taiwan, Rest of Asia-Pacific, Saudi Arabia,  South Africa, Bahrain, Kuwait, Oman, Qatar, U.A.E., Egypt, Israel, and Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.

Мировой рынок лечения SJS/TEN – тенденции отрасли и прогноз до 2030 года

Мировой рынок лечения SJS/TEN – тенденции отрасли и прогноз до 2030 года

Global Sjs Ten Treatment Market

CAGR : 7.60 %

Анализ рынка лечения SJS/TEN и его понимание

Динамика мирового рынка лечения SJS/TEN

Масштаб мирового рынка лечения SJS/TEN

Региональный анализ/информация о мировом рынке лечения SJS/TEN

Конкурентная среда и глобальный анализ доли рынка лечения SJS/TEN

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Отчеты

Обзор рынка

Поддерживать

Решения

Мировой рынок лечения SJS/TEN – тенденции отрасли и прогноз до 2030 года

Мировой рынок лечения SJS/TEN – тенденции отрасли и прогноз до 2030 года

Global Sjs Ten Treatment Market

CAGR : 7.60 %

Анализ рынка лечения SJS/TEN и его понимание

Динамика мирового рынка лечения SJS/TEN

Масштаб мирового рынка лечения SJS/TEN

Региональный анализ/информация о мировом рынке лечения SJS/TEN

Конкурентная среда и глобальный анализ доли рынка лечения SJS/TEN

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Просмотр связанных страниц